Vanda Pharmaceuticals (VNDA) Now Covered by Jefferies Financial Group

Share on StockTwits

Investment analysts at Jefferies Financial Group began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report released on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $26.00 price target on the biopharmaceutical company’s stock. Jefferies Financial Group’s price target would suggest a potential upside of 9.20% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Seaport Global Securities restated a “buy” rating and issued a $26.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday, August 2nd. Cantor Fitzgerald restated a “hold” rating and issued a $26.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 3rd. Oppenheimer set a $27.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Citigroup boosted their price objective on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Finally, Stifel Nicolaus restated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 31st. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.43.

NASDAQ VNDA traded up $0.35 during trading on Thursday, reaching $23.81. The company’s stock had a trading volume of 722,224 shares, compared to its average volume of 608,696. The stock has a market capitalization of $1.07 billion, a PE ratio of -68.03 and a beta of 1.06. Vanda Pharmaceuticals has a 1-year low of $11.90 and a 1-year high of $25.07.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.18. The firm had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $49.44 million. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 6.26%. The company’s revenue was up 18.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.03) earnings per share. On average, analysts expect that Vanda Pharmaceuticals will post -0.04 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the company. Metropolitan Life Insurance Co. NY lifted its stake in shares of Vanda Pharmaceuticals by 18.4% in the second quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock worth $327,000 after buying an additional 2,671 shares during the last quarter. Allianz Asset Management GmbH raised its stake in Vanda Pharmaceuticals by 2.9% during the 1st quarter. Allianz Asset Management GmbH now owns 136,218 shares of the biopharmaceutical company’s stock valued at $2,295,000 after purchasing an additional 3,903 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in Vanda Pharmaceuticals by 20.0% during the 2nd quarter. MetLife Investment Advisors LLC now owns 24,336 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 4,063 shares during the last quarter. Strs Ohio raised its stake in Vanda Pharmaceuticals by 9.7% during the 2nd quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock valued at $904,000 after purchasing an additional 4,200 shares during the last quarter. Finally, Fox Run Management L.L.C. raised its stake in Vanda Pharmaceuticals by 23.9% during the 2nd quarter. Fox Run Management L.L.C. now owns 28,611 shares of the biopharmaceutical company’s stock valued at $545,000 after purchasing an additional 5,516 shares during the last quarter. Institutional investors and hedge funds own 93.92% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

See Also: Investing strategies using the yield curve

Analyst Recommendations for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.